Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP241686.RAwkRfhXobd9iV9CehRunRUBl2sQypxQw1pCXTgSw7tlw130_assertion description "[The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP241686.RAwkRfhXobd9iV9CehRunRUBl2sQypxQw1pCXTgSw7tlw130_provenance.
• NP573482.RARHkCEcAJePH_kt5YQsMsufaPAqehouzkOhFvP6vpXNc130_assertion description "[The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP573482.RARHkCEcAJePH_kt5YQsMsufaPAqehouzkOhFvP6vpXNc130_provenance.
• NP409130.RAPY3bGHKzNRqb223wES4C4cvvfYOiOrDTryeZuvqFP5U130_assertion description "[The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP409130.RAPY3bGHKzNRqb223wES4C4cvvfYOiOrDTryeZuvqFP5U130_provenance.
• assertion description "[The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP525627.RAz0pUOjR5yNr4v8CvP85uZSZEMCyzOieH8W2Aod7qFbs130_assertion description "[The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP525627.RAz0pUOjR5yNr4v8CvP85uZSZEMCyzOieH8W2Aod7qFbs130_provenance.
• NP653058.RAaMa3TiJo42ehHz6H0GZwmTlVTmKMSN_nyprmjXFMUAU130_assertion description "[The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP653058.RAaMa3TiJo42ehHz6H0GZwmTlVTmKMSN_nyprmjXFMUAU130_provenance.
• NP653483.RAWHmbwjiIBIJGlfX0uH-HUnFINCCQT00s6ZcEVXwl3Dc130_assertion description "[The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP653483.RAWHmbwjiIBIJGlfX0uH-HUnFINCCQT00s6ZcEVXwl3Dc130_provenance.
• NP574767.RAFYSldqCb43o2kDYdo6b6oXCysXJzygyHIq8QeQ3lnbQ130_assertion description "[The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP574767.RAFYSldqCb43o2kDYdo6b6oXCysXJzygyHIq8QeQ3lnbQ130_provenance.
• assertion description "[The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP1053371.RAQXZZr0IRDf8npox7kI11ewO6WEWV4_f3TnDOL49PYiw130_assertion description "[The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1053371.RAQXZZr0IRDf8npox7kI11ewO6WEWV4_f3TnDOL49PYiw130_provenance.
• NP1053374.RAV43vLcFtv1-kkVYzzeiqd5tYqEkKZA1zx81BfAt1fhU130_assertion description "[The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1053374.RAV43vLcFtv1-kkVYzzeiqd5tYqEkKZA1zx81BfAt1fhU130_provenance.
• NP1053385.RAZxH6l9-dvfC37JYcUV7TLsI5_hrPUzB-S6Qp3RvL0Us130_assertion description "[The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1053385.RAZxH6l9-dvfC37JYcUV7TLsI5_hrPUzB-S6Qp3RvL0Us130_provenance.
• NP598856.RAvo6JkQsxieeiEcHwuNtqqSQmK6vOig2ubwqtL_31EsQ130_assertion description "[The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP598856.RAvo6JkQsxieeiEcHwuNtqqSQmK6vOig2ubwqtL_31EsQ130_provenance.
• NP1053373.RACs5F88bKyvp47Y_aH8_JfLqwMGrBb2yENPAcEJUPuuo130_assertion description "[The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1053373.RACs5F88bKyvp47Y_aH8_JfLqwMGrBb2yENPAcEJUPuuo130_provenance.
• NP1053376.RACMkkHP9xqbg7N_OJZhJREsNylX6sTMLUdrxhV64ruW8130_assertion description "[The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1053376.RACMkkHP9xqbg7N_OJZhJREsNylX6sTMLUdrxhV64ruW8130_provenance.
• NP475054.RA_arzCzDoT7mXPNyUPSeuAxPye6kzjEAO1sPFKhvYdcU130_assertion description "[The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP475054.RA_arzCzDoT7mXPNyUPSeuAxPye6kzjEAO1sPFKhvYdcU130_provenance.
• NP392667.RAzMcq33B62wUYBGporuHLcyBfTrPrwsCO95zuTRp9OXo130_assertion description "[The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP392667.RAzMcq33B62wUYBGporuHLcyBfTrPrwsCO95zuTRp9OXo130_provenance.
• NP788579.RA7G33p223eXcD1thaj0u_1CnrJQN0Hm2xPrOeTw4AlMY130_assertion description "[The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP788579.RA7G33p223eXcD1thaj0u_1CnrJQN0Hm2xPrOeTw4AlMY130_provenance.
• NP1053377.RA3GhN2PO4gsMf56fPLtgy49FO1oEy-ltsk_WqGaz-taw130_assertion description "[The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1053377.RA3GhN2PO4gsMf56fPLtgy49FO1oEy-ltsk_WqGaz-taw130_provenance.
• NP1053380.RAxJ1QlT8ZACGL7pEiBD6ouh7kHsuv2VxwWziPgNwl_TA130_assertion description "[The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1053380.RAxJ1QlT8ZACGL7pEiBD6ouh7kHsuv2VxwWziPgNwl_TA130_provenance.